Graham Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Graham Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-31,334	Closed	-$943K	–	1538
2025 Q3	$943K	Sell	31,334 -78,754	-72%	-$2.36M	0.01%	404
2025 Q2	$4M	Buy	110,088 +30,612	+39%	+$1.1M	0.06%	183
2025 Q1	$2.88M	Buy	79,476 +20,347	+34%	+$846K	0.05%	229
2024 Q4	$2.49M	Buy	59,129 +16,128	+38%	+$800K	0.04%	246
2024 Q3	$2.39M	Sell	43,001 -12,572	-23%	-$640K	0.04%	238
2024 Q2	$2.28M	Buy	55,573 +11,538	+26%	+$493K	0.05%	218
2024 Q1	$2.06M	Buy	44,035 +30,175	+218%	+$1.42M	0.04%	249
2023 Q4	$663K	Buy	+13,860	New	+$537K	0.01%	502
2022 Q4	–	Sell	-5,936	Closed	-$245K	–	1291
2022 Q3	$245K	Buy	+5,936	New	+$305K	0.01%	957

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Graham Capital Management's RARE Position: Q4 2025 in Review

Graham Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 31,334 shares — an estimated $943K sold.

Graham Capital Management first reported a position in RARE in Q3 2022 and held it in 9 quarters. The position peaked at $4M in Q2 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Graham Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Graham Capital Management sold 31,334 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $943K.
Graham Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and held it in 9 quarters.
Graham Capital Management's Ultragenyx Pharmaceutical position peaked at $4M in Q2 2025.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.